| 臺大學術典藏 |
2020-05-25T07:35:27Z |
Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC
|
Yang J.C.-H.; Chia-Chi Lin; Medema R.H |
| 臺大學術典藏 |
2020-05-25T07:35:25Z |
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
|
Liao B.-C; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:25Z |
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
|
Kao H.-F; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:23Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S; Chia-Chi Lin; Cho D.C; Shapiro G.I; Kwak E.L; Silverman M.H; Tseng Y; Kuo M.-W; Mach W.B; Hsu S.-C; Coleman T; Yang J.C.-H; Cheng A.-L; Ghalib M.H; Chuadhary I; Goel S. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
Chia-Chi Lin; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K.; Srimuninnimit V; Ahn M.-J; Mok T; Kang J.H; Yang J.C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:20Z |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
|
Liao B.-C; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:19Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Yang J.C.-H.; Yu C.-J; Shih J.-Y; Ho C.-C; Chang C.-H; Chen Y.-F; Chia-Chi Lin; Lee J.-H; Liao B.-C |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
Liao B.-C; Chia-Chi Lin; Lee J.-H; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Profile of the therascreen? EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
|
Hsiue E.H.-C; Lee J.-H; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:17Z |
Safety of gefitinib in non-small cell lung cancer treatment
|
Hsiue E.H.-C; Lee J.-H; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:16Z |
Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib
|
Liao B.-C; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib
|
Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.H; Yu C.-J.; Yao Z.-H; Liao W.-Y |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
Liao B.-C; Chia-Chi Lin; Lee J.-H; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:14Z |
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
|
Yang J.C.-H.; Yang Z; Overend P; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; John T; Kim H.R; Chia-Chi Lin; Kim T.M; Ahn J.-S; Lee J.S; Kim S.-W; Cho B.C; Kim D.-W; Ahn M.-J |
| 臺大學術典藏 |
2020-05-25T07:35:13Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Chia-Chi Lin; Shih J.-Y; Yu C.-J; Ho C.-C; Liao W.-Y; Lee J.-H; Tsai T.-H; Su K.-Y; Hsieh M.-S; Chang Y.-L; Bai Y.-Y; Huang D.D.-R; Thress K.S; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:11Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients
|
Wu T.-H; Hsiue E.H.-C; Lee J.-H; Chia-Chi Lin; Liao W.-Y; Ho C.-C; Shih J.-Y; Yu C.-J; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:10Z |
Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?
|
Liao B.-C; Chia-Chi Lin; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:07Z |
Phase I Study of the Focal Adhesion Kinase Inhibitor BI?853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors
|
Chia-Chi Lin;Takeuchi Y;Pronk L.C;Sarashina A;Cheng A.-L;Naito Y;Shitara K;Yang J.C.-H;Doi T; Doi T; Yang J.C.-H; Shitara K; Naito Y; Cheng A.-L; Sarashina A; Pronk L.C; Takeuchi Y; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:05Z |
Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non�Vsmall-cell lung cancer patients
|
Yu C.-J.;Yang J.C.-H;Chia-Chi Lin;Lin Z.-Z;Chen J.-S;Shih J.-Y;Chen K.-Y;Ho C.-C;Liao W.-Y;Yao Z.-H; Yao Z.-H; Liao W.-Y; Ho C.-C; Chen K.-Y; Shih J.-Y; Chen J.-S; Lin Z.-Z; Chia-Chi Lin; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:03Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yu C.-J.; Yang J.C.-H; Shih J.-Y; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Liu Y.-N; Su K.-Y; Chang Y.-L; Wu C.-T; Liao B.-C; Hsu C.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:02Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Chia-Chi Lin; Shih J.-Y; Yang J.C.-H; Yu C.-J. |
| 臺大學術典藏 |
2020-05-25T07:35:01Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Chia-Chi Lin;Tajima N;Oguma T;Ishizuka T;Sugihara M;Chiu L.Y;Sasaki S.-I;Cheng A.-L;Yang J.C.-H;Yen Y.-H;Hsu C.-H;Chen T.W.-W;Lee J.-H; Lee J.-H; Chen T.W.-W; Hsu C.-H; Yen Y.-H; Yang J.C.-H; Cheng A.-L; Sasaki S.-I; Chiu L.Y; Sugihara M; Ishizuka T; Oguma T; Tajima N; Chia-Chi Lin |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
Bogenrieder T; Twelves C; Cheng A.-L.; Huang D.C.-L; Strelkowa N; Goeldner R.-G; Schmid U; Fuertig R; Buschke S; Jove M; Anthoney A; Yen C.-J; de Bono J; Chia-Chi Lin; Chen L.-T; Corral J; Michalarea V; Rihawi K; Ong M; Lee J.-H; Hsu C.-H; Yang J.C.-H; Shiah H.-S |
| 臺大學術典藏 |
2020-05-25T06:51:56Z |
Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas
|
Wu P.-F;Huang W.-C;Yang J.C.-H;Yen-Shen Lu;Shih J.-Y;Wu S.-G;Lin C.-H;Cheng A.-L.; Wu P.-F; Huang W.-C; Yang J.C.-H; YEN-SHEN LU; Shih J.-Y; Wu S.-G; Lin C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:51:54Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Yen-Shen Lu;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Yang J.C.-H.; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; YEN-SHEN LU; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T02:45:35Z |
The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases
|
Chiang Y; Yang J.C.-H; Feng-Ming Hsu; Chen Y.-H; Shih J.-Y; Lin Z.-Z; Lan K.-H; Cheng A.-L; Kuo S.-H. |
| 臺大學術典藏 |
2020-05-25T02:45:33Z |
Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer
|
Lu S.-L; Feng-Ming Hsu; Chen K.-Y; Ho C.-C; Yang J.C.-H; Cheng J.C.-H. |
| 臺大學術典藏 |
2020-05-25T02:45:29Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C;Xiao F;Shih J.-Y;Ho C.-C;Chen Y.-F;Tseng H.-M;Chen K.-Y;Liao W.-Y;Yu C.-J;Yang J.C.-H;Kuo S.-H;Cheng J.C.-H;Yang P.-C;Feng-Ming Hsu; Yang W.-C; Xiao F; Shih J.-Y; Ho C.-C; Chen Y.-F; Tseng H.-M; Chen K.-Y; Liao W.-Y; Yu C.-J; Yang J.C.-H; Kuo S.-H; Cheng J.C.-H; Yang P.-C; Feng-Ming Hsu |
| 臺大學術典藏 |
2020-05-25T02:45:22Z |
Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors
|
Lee J.-H;Chen H.-Y;Feng-Ming Hsu;Chen J.-S;Liao W.-Y;Shih J.-Y;Yu C.-J;Chen K.-Y;Tsai T.-H;Yang J.C.-H.; Lee J.-H; Chen H.-Y; Feng-Ming Hsu; Chen J.-S; Liao W.-Y; Shih J.-Y; Yu C.-J; Chen K.-Y; Tsai T.-H; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-25T01:33:01Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
YEN-TING LIN; Wang Y.-F.; Yang J.C.-H.; Yu C.-J.; Wu S.-G.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-05-25T01:33:00Z |
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review
|
YEN-TING LIN; Yu C.-J.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:59Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
|
YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-25T01:32:58Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-05-20T05:11:45Z |
Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer
|
Wu S.-G.; Shih J.-Y.; Yang P.-C.; Yu C.-J.; Yang J.C.-H.; Wang Y.-F.; YEN-TING LIN; Yang P.-C.;Shih J.-Y.;Wu S.-G.;Yu C.-J.;Yang J.C.-H.;Wang Y.-F.;YEN-TING LIN |
| 臺大學術典藏 |
2020-05-20T05:11:44Z |
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non�VSmall-Cell Lung Cancer: Analysis and Literature Review
|
Yang J.C.-H.; Yu C.-J.; YEN-TING LIN; Shih J.-Y.;Yang J.C.-H.;Yu C.-J.;YEN-TING LIN; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:43Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non�VSmall-cell Lung Cancer
|
Shih J.-Y.;Yang J.C.-H.;Wu S.-G.;Liu Y.-N.;YEN-TING LIN; YEN-TING LIN; Liu Y.-N.; Wu S.-G.; Yang J.C.-H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-05-20T05:11:42Z |
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
|
Yu C.-J.;Yang J.C.-H.;Shih J.-Y.;Lin Z.-Z.;Lee J.-H.;Chen K.-Y.;Yang C.-Y.;Hsu C.-L.;Ho C.-C.;Liao W.-Y.;Chen J.-S.;YEN-TING LIN; YEN-TING LIN; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:09Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
Cheng A.-L.; Twelves C.; Bogenrieder T.; Huang D.C.-L.; Strelkowa N.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Shiah H.-S.; Yang J.C.-H.; CHIH-HUNG HSU; Lee J.-H.; de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; De Bono J.;Lin C.-C.;Chen L.-T.;Corral J.;Michalarea V.;Rihawi K.;Ong M.;Lee J.-H.;Chih-Hung Hsu;Yang J.C.-H.;Shiah H.-S.;Yen C.-J.;Anthoney A.;Jove M.;Buschke S.;Fuertig R.;Schmid U.;Goeldner R.-G.;Strelkowa N.;Huang D.C.-L.;Bogenrieder T.;Twelves C.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:08Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
Lee J.-H.; Lee J.-H.;Chen T.W.-W.;Chih-Hung Hsu;Yen Y.-H.;Yang J.C.-H.;Cheng A.-L.;Sasaki S.-I.;Chiu L.Y.;Sugihara M.;Ishizuka T.;Oguma T.;Tajima N.;Lin C.-C.; Chen T.W.-W.; CHIH-HUNG HSU; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2020-04-27T08:45:08Z |
Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery
|
Yang W.-C.;Xiao F.;Shih J.-Y.;Ho C.-C.;Chen Y.-F.;Tseng H.-M.;Chen K.-Y.;Liao W.-Y.;Yu C.-J.;Yang J.C.-H.;Kuo S.-H.;Chia-Hsien Cheng;Yang P.-C.;Hsu F.-M.; Yang W.-C.; Xiao F.; Shih J.-Y.; Ho C.-C.; Chen Y.-F.; Tseng H.-M.; Chen K.-Y.; Liao W.-Y.; Yu C.-J.; Yang J.C.-H.; Kuo S.-H.; CHIA-HSIEN CHENG; Yang P.-C.; Hsu F.-M. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:10Z |
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
|
Lin Z.-Z.; Shau W.-Y.; Chiun Hsu; Shao Y.-Y.; Yeh Y.-C.; Kuo R.N.-C.; Hsu C.-H.; Yang J.C.-H.; Cheng A.-L.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:51:09Z |
Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers
|
Kao H.-F.;Chen I.-C.;Chiun Hsu;Chang S.-Y.;Chien S.-F.;Chen Y.-C.;Hu F.-C.;Yang J.C.-H.;Cheng A.-L.;Yeh K.-H.; Kao H.-F.; Chen I.-C.; Chiun Hsu; Chang S.-Y.; Chien S.-F.; Chen Y.-C.; Hu F.-C.; Yang J.C.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:05Z |
The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia
|
Kuo H.-Y.;Lin Z.-Z.;Kuo R.;Shau W.-Y.;Lai C.-L.;Yang Y.-Y.;Shao Y.-Y.;Chiun Hsu;Cheng W.-F.;Cheng A.-L.;Yang J.C.H.;Lai M.-S.; Kuo H.-Y.; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Chiun Hsu; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:11Z |
Survival of patients with small cell lung carcinoma in Taiwan
|
Kuo Y.-H.; Lin Z.-Z.; Yang Y.-Y.; YU-YUN SHAO; Shau W.-Y.; Kuo R.N.C.; Yang J.C.-H.; Lai M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:10Z |
Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study
|
Lin Z.-Z.; Shau W.-Y.; YU-YUN SHAO; Yang Y.-Y.; Kuo R.N.-C.; Yang J.C.-H.; Laie M.-S. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
|
YU-YUN SHAO; Shau W.-Y.; Lin Z.-Z.; Chen H.-M.; Kuo R.; Yang J.C.-H.; Lai M.-S. |
